Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 4
2005 11
2006 10
2007 6
2008 7
2010 2
2011 2
2012 1
2013 1
2014 1
2017 2
2018 4
2019 3
2020 4
2021 7
2022 4
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
Phenotypic characterization of disease-initiating stem cells in JAK2- or CALR-mutated myeloproliferative neoplasms.
Ivanov D, Milosevic Feenstra JD, Sadovnik I, Herrmann H, Peter B, Willmann M, Greiner G, Slavnitsch K, Hadzijusufovic E, Rülicke T, Dahlhoff M, Hoermann G, Machherndl-Spandl S, Eisenwort G, Fillitz M, Sliwa T, Krauth MT, Bettelheim P, Sperr WR, Koller E, Pfeilstöcker M, Gisslinger H, Keil F, Kralovics R, Valent P. Ivanov D, et al. Among authors: krauth mt. Am J Hematol. 2023 May;98(5):770-783. doi: 10.1002/ajh.26889. Epub 2023 Mar 9. Am J Hematol. 2023. PMID: 36814396 Free PMC article.
Pathway-Directed Therapy in Multiple Myeloma.
John L, Krauth MT, Podar K, Raab MS. John L, et al. Among authors: krauth mt. Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668. Cancers (Basel). 2021. PMID: 33916289 Free PMC article. Review.
Paraneoplastic autoimmune thrombocytopenia in solid tumors.
Krauth MT, Puthenparambil J, Lechner K. Krauth MT, et al. Crit Rev Oncol Hematol. 2012 Jan;81(1):75-81. doi: 10.1016/j.critrevonc.2011.02.004. Epub 2011 Apr 22. Crit Rev Oncol Hematol. 2012. PMID: 21515071 Review.
[Bisphosphonate-associated osteonecrosis of the jaw].
Krauth MT, Fügl A, Gruber R. Krauth MT, et al. Wien Klin Wochenschr. 2008;120(15-16):467-76. doi: 10.1007/s00508-008-1002-9. Wien Klin Wochenschr. 2008. PMID: 18820850 Review. German.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Among authors: krauth mt. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Clinical Trial.
Austrian recommendations for the management of essential thrombocythemia.
Buxhofer-Ausch V, Heibl S, Sliwa T, Beham-Schmid C, Wolf D, Geissler K, Krauth MT, Krippl P, Petzer A, Wölfler A, Melchardt T, Gisslinger H. Buxhofer-Ausch V, et al. Among authors: krauth mt. Wien Klin Wochenschr. 2021 Jan;133(1-2):52-61. doi: 10.1007/s00508-020-01761-3. Epub 2020 Nov 19. Wien Klin Wochenschr. 2021. PMID: 33215234
67 results